
TransMedics Group EBITDA | TMDX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA TransMedics Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136 M | 57.3 M | -20.6 M | -28 M | -37.6 M | -24.8 M | -28.4 M | -19.5 M | -19.8 M | -22.6 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 136 M | -37.6 M | -811 K |
Quarterly EBITDA TransMedics Group
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.3 M | 34 M | 25.2 M | 21.3 M | 23.4 M | 36.7 M | 27.5 M | 8.64 M | 4.02 M | 12.6 M | 12.5 M | -1.87 M | -26.4 M | 486 K | -802 K | -5.49 M | -4.65 M | -8.95 M | -8.86 M | -10.9 M | -11.3 M | -9.42 M | -6.06 M | -5.47 M | -4.21 M | -7.49 M | -7.65 M | -8.34 M | -6.91 M | -7.42 M | -5.72 M | -6.36 M | -3.39 M | -4.82 M | -4.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.7 M | -26.4 M | 1.93 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
-18 M | - | - | $ 162 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Zynex
ZYXI
|
8.89 M | - | - | $ 21.1 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 46.69 | 0.39 % | $ 1.45 B | ||
|
ShockWave Medical
SWAV
|
169 M | - | - | $ 12.3 B | ||
|
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Axonics Modulation Technologies
AXNX
|
-13.6 M | - | - | $ 3.31 B | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
ThermoGenesis Holdings
THMO
|
-7.46 M | - | -25.84 % | $ 171 K | ||
|
Talis Biomedical Corporation
TLIS
|
-66 M | - | 3.55 % | $ 7.96 M | ||
|
Abiomed
ABMD
|
169 M | - | - | $ 17.2 B | ||
|
Titan Medical
TMDI
|
-31 M | - | -26.32 % | $ 19.6 M | ||
|
SmileDirectClub
SDC
|
-188 M | - | -53.45 % | $ 9.71 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Sientra
SIEN
|
-62.4 M | - | -16.59 % | $ 10.3 M | ||
|
Acutus Medical
AFIB
|
240 K | - | -26.83 % | $ 2.62 M | ||
|
Viveve Medical
VIVE
|
-20.4 M | - | -15.35 % | $ 1.71 M | ||
|
MiMedx Group
MDXG
|
78.8 M | $ 3.06 | -1.77 % | $ 452 M | ||
|
Venus Concept
VERO
|
-23.3 M | - | - | $ 726 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Surgalign Holdings
SRGA
|
-76.3 M | - | -32.98 % | $ 1.68 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
SeaSpine Holdings Corporation
SPNE
|
-47 M | - | 0.28 % | $ 270 M | ||
|
Inari Medical
NARI
|
-7.14 M | - | - | $ 4.23 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
ViewRay
VRAY
|
-102 M | - | 1.54 % | $ 468 M | ||
|
Medigus Ltd.
MDGS
|
-8.02 M | - | 10.28 % | $ 55.5 M | ||
|
Abbott Laboratories
ABT
|
9.49 B | $ 103.08 | -0.98 % | $ 179 B | ||
|
Align Technology
ALGN
|
783 M | $ 154.77 | -3.07 % | $ 11.2 B | ||
|
Vapotherm
VAPO
|
-34.1 M | - | 6.72 % | $ 34 M | ||
|
Silk Road Medical, Inc
SILK
|
-56.6 M | - | - | $ 1.07 B | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 6.66 | -3.48 % | $ 999 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 41.95 | -2.43 % | $ 62.1 B | ||
|
Natus Medical Incorporated
NTUS
|
51.9 M | - | 1.94 % | $ 1.05 B | ||
|
Nemaura Medical
NMRD
|
-9.15 M | - | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
-79.7 M | $ 5.39 | -8.28 % | $ 1.33 B | ||
|
Bio-Rad Laboratories
BIO
|
213 M | $ 358.56 | -2.43 % | $ 9.78 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 101.86 | -1.94 % | $ 59.6 B | ||
|
Aethlon Medical
AEMD
|
-6.97 M | $ 5.49 | 13.33 % | $ 3.7 M | ||
|
Apyx Medical Corporation
APYX
|
-5.79 M | $ 2.39 | 2.06 % | $ 98.2 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 7.27 | -6.56 % | $ 530 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Medtronic PLC
MDT
|
9.42 B | $ 99.64 | -1.0 % | $ 128 B |